| Literature DB >> 34557040 |
Søren Mose1,2, Peter Kent3,4, Anne Smith3, Johan Hviid Andersen1, David Høyrup Christiansen1.
Abstract
BACKGROUND AND AIM: Chronic musculoskeletal pain is common and associated with more general healthcare-seeking. However, musculoskeletal-related healthcare utilization is under-explored. This study aimed to explore, describe and profile trajectories of long-term musculoskeletal healthcare for people reporting chronic musculoskeletal pain.Entities:
Keywords: chronic musculoskeletal pain; healthcare registers; healthcare utilization; latent class growth analysis; musculoskeletal
Year: 2021 PMID: 34557040 PMCID: PMC8455515 DOI: 10.2147/CLEP.S323903
Source DB: PubMed Journal: Clin Epidemiol ISSN: 1179-1349 Impact factor: 4.790
Figure 1Flowchart.
Algorithm for Counting Annual Number of Musculoskeletal Healthcare Contacts
| Annual Number of Musculoskeletal Healthcare Contacts is Generated by | |
|---|---|
| National Patient Register | 1)Counts of in- and out-patient hospital contacts and emergency department contacts registered with a primary or secondary musculoskeletal or pain-related ICD-10 diagnostic code. Every inpatient admission day counted as one contact. Please see supplementary material ( |
| National Health Insurance Service Register | 2)Counts of face-to-face primary healthcare consultations with physiotherapists, chiropractors and musculoskeletal medical specialists. Excluded in this category was fully publicly reimbursed encounters with physiotherapists for non-musculoskeletal diagnoses. |
| National Health Insurance Service Register | 3)Counts of face-to-face GP contacts where the clinical tests, examination, coding and subsequent healthcare initiatives indicated a musculoskeletal reason for that consultation. For this purpose, a simple algorithm was developed. The algorithm evaluated each face-to-face GP contact in two steps and built on available information from all health registers. For a more detailed description, please see supplementary material ( |
| Register of Medicinal Product Statistics | 4)Counts of prescribed and redeemed medication for pain relief. We searched the Register of Medicinal Product Statistics using the Anatomical Therapeutic Chemical Classification System codes for N01B (Anesthetics, local), N02A + B (Opioids, other analgesics and antipyretics), N03A (Antiepileptic), N05B + C (Anxiolytics and Hypnotics) and M01A (Anti-inflammatory/anti-rheumatic, non-steroids). |
| Rehab-register | 5)Counts of face-to-face municipality musculoskeletal rehabilitation visits indicated by a prior musculoskeletal hospital in- or out-patient contact. |
Distribution of Individual and Sociodemographic Factors Across the Five Trajectory Groups
| Total | Group 1 Low Stable | Group 2 Low Ascending | Group 3 Low Descending | Group 4 Medium Stable | Group 5 High Stable | Overall Test p-value | Pairwise Comparison Between Low Stable/High Stable Group and All Other Trajectory Groups | |
|---|---|---|---|---|---|---|---|---|
| N=2929 | N=1151 | N=486 | N=600 | N=463 | N=229 | |||
| Sex, n (%) | <0.001 | Group 1 ≠ Group 2,3,4,5 Group 5 ≠ Group 1,2,3 | ||||||
| Men | 1263 (43.1%) | 605 (52.6%) | 199 (40.9%) | 260 (43.3%) | 143 (30.9%) | 56 (24.5%) | ||
| Women | 1666 (56.9%) | 546 (47.4%) | 287 (59.1%) | 340 (56.7%) | 320 (69.1%) | 173 (75.5%) | ||
| Age at baseline, mean (sd) | 46.9 (12.0) | 45.3 (12.6) | 46.5 (12.2) | 47.7 (11.7) | 48.8 (10.7) | 49.7 (10.4) | <0.001 | Group 1 ≠ Group 3,4,5 Group 5 ≠ Group 1,2 |
| Marital Status, n (%) (a) | <0.001 | Group 1 ≠ Group 4,5 Group 5 ≠ Group 1,2,3 | ||||||
| Cohabitant with children | 1005 (34.3%) | 451 (39.2%) | 173 (35.6%) | 193 (32.2%) | 143 (31.0%) | 45 (19.7%) | ||
| Cohabitant without children | 1307 (44.6%) | 465 (40.4%) | 207 (42.6%) | 285 (47.5%) | 217 (47.0%) | 133 (58.1%) | ||
| Single with children | 130 (4.4%) | 42 (3.6%) | 26 (5.3%) | 24 (4.0%) | 28 (6.1%) | 10 (4.4%) | ||
| Single without children | 486 (16.6%) | 193 (16.8%) | 80 (16.5%) | 98 (16.3%) | 74 (16.0%) | 41 (17.9%) | ||
| Highest level of education, n (%) | <0.001 | Group 1 ≠ Group 4,5 Group 5 ≠ Group 1,2,3 | ||||||
| Primary school/high school | 443 (15.1%) | 179 (15.6%) | 66 (13.6%) | 78 (13.0%) | 70 (15.1%) | 50 (21.8%) | ||
| Skilled worker/short-term education | 1637 (55.9%) | 602 (52.3%) | 275 (56.6%) | 347 (57.8%) | 282 (60.9%) | 131 (57.2%) | ||
| Long/medium-term higher education | 849 (29.0%) | 370 (32.1%) | 145 (29.8%) | 175 (29.2%) | 111 (24.0%) | 48 (21.0%) | ||
| Extraversion (Mini-IPIP), mean (sd) (b) | 8.4 (3.1) | 8.3 (3.0) | 8.6 (3.0) | 8.6 (3.2) | 8.5 (3.0) | 7.9 (3.2) | 0.004 | Group 5 ≠ Group 2,3 |
| Agreeableness (Mini-IPIP), mean (sd) (c) | 11.6 (2.2) | 11.4 (2.2) | 11.6 (2.2) | 11.7 (2.2) | 11.8 (2.2) | 12.0 (2.1) | <0.001 | Group 1 ≠ Group 4,5 Group 5 ≠ Group 1,2 |
| Conscientiousness (Mini-IPIP), mean (sd) (d) | 10.7 (3.0) | 10.5 (3.0) | 10.6 (2.9) | 10.9 (2.9) | 10.8 (3.2) | 10.6 (3.1) | 0.084 | |
| Neuroticism (Mini-IPIP), mean (sd) (e) | 6.8 (3.0) | 6.2 (2.8) | 6.6 (2.9) | 6.8 (3.0) | 7.5 (3.0) | 8.6 (3.3) | <0.001 | Group 1 ≠ Group 2,3,4,5 Group 5 ≠ Group 1,2,3,4 |
| Imagination (Mini-IPIP), mean (sd) (f) | 8.9 (3.1) | 9.1 (3.1) | 9.1 (3.1) | 8.8 (3.2) | 8.9 (3.0) | 8.3 (3.1) | 0.009 | Group 1 ≠ Group 5 Group 5 ≠ Group 1,2 |
Note: Missings: (a) 1. (b) 62. (c) 67. (d) 83. (e) 60. (f) 74.
Distribution of Health, Belief and Work-Related Factors Across the Five Trajectory Groups
| Total | Group 1 Low Stable | Group 2 Low Ascending | Group 3 Low Descending | Group 4 Medium Stable | Group 5 High Stable | Overall Test p-value | Pairwise Comparison Between Low Stable/High Stable Group and All Other Trajectory Groups | |
|---|---|---|---|---|---|---|---|---|
| N=2929 | N=1151 | N=486 | N=600 | N=463 | N=229 | |||
| Baseline BMI Groups, n (%) (a) | <0.001 | Group 1 ≠ Group 5 Group 5 ≠ Group 1,2,3,4 | ||||||
| Under/Normal weight (<24.9) | 1395 (48.8%) | 589 (52.4%) | 237 (49.6%) | 288 (49.1%) | 207 (46.0%) | 74 (33.8%) | ||
| Pre-obesity (25–29.9), n(%) | 1061 (37.1%) | 404 (35.9%) | 171 (35.8%) | 218 (37.1%) | 177 (39.3%) | 91 (41.6%) | ||
| Obesity Class I (30–34.9) | 302 (10.6%) | 103 (9.2%) | 51 (10.7%) | 63 (10.7%) | 45 (10.0%) | 40 (18.3%) | ||
| Obesity Class II & III (>35) | 100 (3.5%) | 28 (2.5%) | 19 (4.0%) | 18 (3.1%) | 21 (4.7%) | 14 (6.4%) | ||
| Number of painsites, mean (sd) (b) | 3.7 (1.8) | 3.3 (1.7) | 3.7 (1.8) | 3.8 (1.8) | 4.3 (1.7) | 4.7 (1.8) | <0.001 | Group 1 ≠ Group 2,3,4,5 Group 5 ≠ Group 1,2,3 |
| Pain intensity, mean (sd) (c) | 4.1 (1.5) | 3.6 (1.4) | 4.1 (1.4) | 4.2 (1.4) | 4.6 (1.4) | 5.2 (1.2) | <0.001 | Group 1 ≠ Group 2,3,4,5 Group 5 ≠ Group 1,2,3,4 |
| Physical health (PCS - SF 12), mean (sd) (d) | 42.0 (4.6) | 41.6 (4.4) | 41.8 (4.7) | 42.3 (4.7) | 42.9 (4.8) | 42.3 (5.1) | <0.001 | Group 1 ≠ Group 3,4 |
| Mental health (MCS - SF 12), mean (sd) (e) | 48.5 (5.9) | 48.8 (5.4) | 48.6 (5.6) | 48.4 (5.8) | 47.6 (6.8) | 47.8 (6.9) | 0.003 | Group 1 ≠ Group 4,5 Group 5 ≠ Group 1 |
| Signs of depression (SCL-DEP6), n (%) (f) | <0.001 | Group 1 ≠ Group 3,4,5 Group 5 ≠ Group 1,2,3,4 | ||||||
| Low score | 2330 (80.6%) | 982 (86.2%) | 404 (84.2%) | 481 (81.0%) | 327 (71.7%) | 136 (61.0%) | ||
| High score | 562 (19.4%) | 157 (13.8%) | 76 (15.8%) | 113 (19.0%) | 129 (28.3%) | 87 (39.0%) | ||
| Signs of anxiety (SCL-ANX4), n (%) (g) | <0.001 | Group 1 ≠ Group 2,3,4,5 Group 5 ≠ Group 1,2,3 | ||||||
| Low score | 2508 (86.7%) | 1055 (92.6%) | 421 (87.3%) | 512 (86.1%) | 354 (77.8%) | 166 (74.4%) | ||
| High score | 386 (13.3%) | 84 (7.4%) | 61 (12.7%) | 83 (13.9%) | 101 (22.2%) | 57 (25.6%) | ||
| Health anxiety (Whiteley-7), n (%) (h) | <0.001 | Group 1 ≠ Group 3,4,5 Group 5 ≠ Group 1,2,3 | ||||||
| Low score | 2166 (75.2%) | 947 (83.3%) | 375 (78.1%) | 434 (73.6%) | 288 (63.7%) | 122 (54.7%) | ||
| High score | 716 (24.8%) | 190 (16.7%) | 105 (21.9%) | 156 (26.4%) | 164 (36.3%) | 101 (45.3%) | ||
| Participation restriction due to pain, n (%) (i) | <0.001 | Group 1 ≠ Group 2,3,4,5 Group 5 ≠ Group 1,2,3,4 | ||||||
| Low degree of restriction | 1631 (56.9%) | 785 (69.8%) | 299 (62.0%) | 303 (51.7%) | 191 (42.4%) | 53 (24.0%) | ||
| High degree of restriction | 1233 (43.1%) | 339 (30.2%) | 183 (38.0%) | 283 (48.3%) | 260 (57.6%) | 168 (76.0%) | ||
| Fear avoidance beliefs, mean (sd) (j) | 11.2 (4.2) | 10.9 (4.2) | 10.9 (4.1) | 11.3 (4.3) | 11.3 (4.2) | 13.0 (4.4) | <0.001 | Group 1 ≠ Group 5 Group 5 ≠ Group 1,2,3,4 |
| Charlson Comorbidity Index - Baseline, n (%) | <0.001 | Group 1 ≠ Group 4.5 Group 5 ≠ Group 1,2,3,4 | ||||||
| No comorbidity | 2758 (94.2%) | 1113 (96.7%) | 459 (94.4%) | 569 (94.8%) | 424 (91.6%) | 193 (84.3%) | ||
| Comorbidity score = 1 | 101 (3.4%) | 19 (1.7%) | 10 (2.1%) | 17 (2.8%) | 32 (6.9%) | 23 (10.0%) | ||
| Comorbidity score ≥2 | 70 (2.4%) | 19 (1.7%) | 17 (3.5%) | 14 (2.3%) | 7 (1.5%) | 13 (5.7%) | ||
| Charlson Comorbidity Index - End of Follow-up, n (%) | <0.001 | Group 1 ≠ 2,3,4,5 Group 5 ≠ 1,2,3,4 | ||||||
| No comorbidity | 2283 (77.9%) | 985 (85.6%) | 382 (78.6%) | 466 (77.7%) | 321 (69.3%) | 129 (56.3%) | ||
| Comorbidity score = 1 | 297 (10.1%) | 74 (6.4%) | 35 (7.2%) | 58 (9.7%) | 81 (17.5%) | 49 (21.4%) | ||
| Comorbidity score ≥2 | 349 (11.9%) | 92 (8.0%) | 69 (14.2%) | 76 (12.7%) | 61 (13.2%) | 51 (22.3%) | ||
| MSK-contacts in 2006 and 2007, n (%) | <0.001 | Group 1 ≠ 2,3,4,5 Group 5 ≠ 1,2,3,4 | ||||||
| No MSK-contacts | 1331 (45.4%) | 783 (68.0%) | 266 (54.7%) | 180 (30.0%) | 91 (19.7%) | 11 (4.8%) | ||
| One MSK-contact | 242 (8.3%) | 94 (8.2%) | 46 (9.5%) | 62 (10.3%) | 30 (6.5%) | 10 (4.4%) | ||
| 2–7 MSK-contacts | 674 (23.0%) | 201 (17.5%) | 106 (21.8%) | 167 (27.8%) | 137 (29.6%) | 63 (27.5%) | ||
| > 8 MSK-contacts | 682 (23.3%) | 73 (6.3%) | 68 (14.0%) | 191 (31.8%) | 205 (44.3%) | 145 (63.3%) | ||
| Labor market status, n (%) | <0.001 | Group 1 ≠ Group 2,3,4,5 Group 5 ≠ Group 1,2,3,4 | ||||||
| Working or student | 1877 (64.1%) | 855 (74.3%) | 348 (71.6%) | 367 (61.2%) | 240 (51.8%) | 67 (29.3%) | ||
| Unemployed | 119 (4.1%) | 66 (5.7%) | 11 (2.3%) | 26 (4.3%) | 10 (2.2%) | 6 (2.6%) | ||
| Health-related benefit | 333 (11.4%) | 38 (3.3%) | 30 (6.2%) | 57 (9.5%) | 103 (22.2%) | 105 (45.9%) | ||
| Retirement | 600 (20.5%) | 192 (16.7%) | 97 (20.0%) | 150 (25.0%) | 110 (23.8%) | 51 (22.3%) |
Note: Missings: (a) 71. (b) 63. (c) 17. (d) 164. (e) 164. (f) 37. (g) 35. (h) 47. (i) 65. (j) 69.
Figure 2Trajectories of musculoskeletal (MSK) healthcare utilization for people reporting chronic musculoskeletal pain.
Figure 3Annual number of musculoskeletal primary, secondary and rehabilitation healthcare contacts and annual number of redeemed medication prescriptions for pain relief stratified by trajectory groups.
Distribution of Participants and the Characteristics of Musculoskeletal Healthcare Utilization Trajectories for People Reporting Chronic Musculoskeletal Pain
| Group 1 Low Stable | Group 2 Low Ascending | Group 3 Low Descending | Group 4 Medium Stable | Group 5 High Stable | ||
|---|---|---|---|---|---|---|
| N = 2929.n (%) | 1151 (39.4%) | 486 (16.6%) | 600 (20.4%) | 463 (15.8%) | 229 (7.8%) | |
| Posterior probability of trajectory group membership Mean (SD) | 98.9% (0.1%) | 96.9% (0.1%) | 97.5% (0.1%) | 98.4% (0.1%) | 98.9% (0.1%) | |
| General trajectory characteristics | No or very few (<3) annual musculoskeletal healthcare contacts consistently throughout the follow-up period. | No or very few annual musculoskeletal healthcare contacts at beginning of follow-up increasing to between five and ten annual contacts at end of follow-up. | Between five and ten annual musculoskeletal healthcare contacts at beginning of follow-up decreasing to very few contacts at end of follow-up | Around ten annual musculoskeletal healthcare contacts. Slightly increasing trend of number of contacts over the follow-up period. | Twenty to twenty-five annual musculoskeletal healthcare contacts throughout the follow-up period. Peak years for some individuals with more than 100 musculoskeletal contacts | |
| Median, Interquartile range (IQR) of musculoskeletal healthcare contacts | 2008 | 0 (0–0) | 0 (0–1) | 3 (0–8) | 6 (1–12) | 22 (14–36) |
| 2009 | 0 (0–0) | 0 (0–1) | 3 (0–8) | 7 (2–12) | 24 (14–38) | |
| 2010 | 0 (0–0) | 0 (0–1) | 3 (0–7) | 6 (3–11) | 23 (14–36) | |
| 2011 | 0 (0–0) | 0 (0–1) | 3 (0–7) | 7 (3–12) | 25 (16–40) | |
| 2012 | 0 (0–0) | 0 (0–2) | 2 (0–5) | 7 (4–12) | 25 (15–37) | |
| 2013 | 0 (0–0) | 0 (0–3) | 2 (0–5) | 8 (4–14) | 24 (15–38) | |
| 2014 | 0 (0–0) | 3 (0–8) | 1 (0–4) | 9 (5–15) | 27 (15–39) | |
| 2015 | 0 (0–0) | 5 (1–10) | 0 (0–3) | 10 (6–17) | 27 (15–41) | |
| 2016 | 0 (0–0) | 5 (2–10) | 0 (0–3) | 9 (5–16) | 24 (14–39) | |
| 2017 | 0 (0–0) | 4 (1–10) | 1 (0–3,5) | 9 (5–16) | 24 (13–36) | |
Total Number of Contacts and Proportions of Number of Contacts in Primary and Secondary Healthcare, Redeemed Medication for Pain Relief and Rehabilitation Within Trajectory Groups
| Group 1 Low Stable | Group 2 Low Ascending | Group 3 Low Descending | Group 4 Medium Stable | Group 5 High Stable | |
|---|---|---|---|---|---|
| Total number of contacts from 2008–2017 | 5950 | 16,637 | 22,625 | 48,254 | 66,979 |
| Total number of contacts (proportions) | 3096 (52%) | 8618 (52%) | 13,519 (60%) | 23,747 (49%) | 25,909 (39%) |
| - Total number of contacts (proportions) | 950 (16%) | 1792 (11%) | 2370 (10%) | 4250 (9%) | 4032 (6%) |
| - Total number of contacts (proportions) | 1840 (31%) | 5303 (32%) | 5935 (26%) | 18,121 (38%) | 35,544 (53%) |
| - Total number of contacts (proportions) | 64 (1%) | 924 (6%) | 801 (4%) | 2136 (4%) | 1494 (2%) |